These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21957991)

  • 1. Translational research to realize the full potential of novel agents--an opportunity for vinflunine?
    Yip AY; Ong EY; Chow LW
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S5-8. PubMed ID: 21957991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
    Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
    Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinflunine: a new microtubule inhibitor agent.
    Bennouna J; Delord JP; Campone M; Nguyen L
    Clin Cancer Res; 2008 Mar; 14(6):1625-32. PubMed ID: 18347163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
    Bellmunt J; Delgado FM; George C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
    Ng JS
    J Oncol Pharm Pract; 2011 Sep; 17(3):209-24. PubMed ID: 20584744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinflunine.
    Prescrire Int; 2011 Jan; 20(112):11-3. PubMed ID: 21462785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
    Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
    BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.
    Abdel-Malek R; Shohdy KS; Abbas N; Ismail M; Hamada E; Abdel-Kader Y
    Curr Drug Saf; 2019; 14(1):31-36. PubMed ID: 30277164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
    Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK
    Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinflunine in the treatment of advanced bladder cancer.
    Mamtani R; Vaughn DJ
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):13-20. PubMed ID: 21166506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy.
    Gerullis H
    Drugs Today (Barc); 2011 Jan; 47(1):17-25. PubMed ID: 21373647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.
    Gerullis H; Ecke TH; Janusch B; Arndt C; Heidari M; Oniani J; Otto T
    Anticancer Drugs; 2011 Oct; 22(9):940-3. PubMed ID: 21642839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
    Sonpavde G; Rosenberg JE; Hahn NM; Galsky MD; Bangs R; Sternberg CN; Vogelzang NJ
    J Clin Oncol; 2010 May; 28(13):e205-7; author reply e208. PubMed ID: 20159797
    [No Abstract]   [Full Text] [Related]  

  • 15. Second-line therapy in bladder cancer.
    Bachner M; De Santis M
    Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
    Hussain SA; Ansari J; Huddart R; Power DG; Lyons J; Wylie J; Vilarino-Varlela M; Elander NO; McMenemin R; Pickering LM; Faust G; Chauhan S; Jackson RJ
    Int J Oncol; 2017 Mar; 50(3):768-772. PubMed ID: 28098864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination chemotherapy with bleomycin, vinca alkaloid and cisplatin (BVP) for advanced urothelial cancer].
    Sekine H; Fukui I; Yamada T; Takeuchi S; Tachibana Y; Yokokawa M
    Hinyokika Kiyo; 1984 Aug; 30(8):1095-9. PubMed ID: 6083719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.
    Heers H; DE Geeter P; Goebell PJ; Matz U; DE Schultz W; Edlich B; Retz M; Hegele A
    Anticancer Res; 2017 Nov; 37(11):6437-6442. PubMed ID: 29061830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
    Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series.
    Palumbo R; Licata L; Sottotetti F; Tagliaferri B; Pozzi E; Teragni C; Quaquarini E; Bernardo A
    Oncol Res Treat; 2018; 41(1-2):8-13. PubMed ID: 29402855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.